Ulcerative Colitis
Conditions
Interventions
Observation Group:Mesalazine enteric-coated tablets, oral: 1.0 g per dose, three times daily
Boulardii Sachets, oral: 0.5 g per dose, twice daily.
Control Group:Mesalazine enteric-coated tablets, oral: 1.0 g per dose, three times daily
Boulardii Sachets placebo, oral: 0.5 g per dose, twice daily.
Sponsors
The Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for ulcerative colitis outlined in the "Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023, Xi’an)" [18]; 2.Aged 18–80 years, with no restriction on sex; 3. No severe cardiovascular, hepatic, renal, or endocrine system diseases; 4. Voluntarily signs an informed consent form to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Patients who have used other probiotic medications within the past 7 days; 2.Patients currently taking antifungal medications; 3. Patients with central venous catheters; 4. Pregnant or lactating women; 5.Patients allergic to the medications used in this study; 6. Patients currently enrolled in other clinical studies; 7.Any other conditions deemed unsuitable for participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mayo Clinical Score;C-reactive protein;Erythrocyte Sedimentation Rate;Calprotectin;Gut microbiota;Metabolomics Analysis;Mesalazine Blood Concentration;Disease-Related Computational Index;Time of disappearance of clinical symptoms; | — |
Countries
China
Contacts
Public ContactZhong Xiaolin
The Affiliated Hospital of Southwest Medical University
Outcome results
None listed